According to HB 307, the only patients who could qualify would be those who have a “terminal condition that is attested to by the patient’s physician and confirmed by a second independent evaluation by a board-certified physician in an appropriate specialty for that condition” and “considered all other treatment options for the terminal condition currently approved by the United States Food and Drug Administration.”